Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 3

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 10Thoracic 4Lymphoid 3Genitourinary 3Dermatologic 3Other hematologic neoplasm 2Gastrointestinal 2NET 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × entinostat × Genitourinary × Clear all
NCT03978624 2025-10-15

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
20 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms

NCT03552380 2024-09-03

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Hoosier Cancer Research Network

Phase 2 Terminated
12 enrolled 16 charts
Genitourinary

Carcinoma, Renal Cell

NCT03501381 2023-09-01

High Dose IL 2 and Entinostat in RCC

Hoosier Cancer Research Network

Phase 2 Active not recruiting
46 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡